Medacta Group revenue update and why it matters for investors
Medacta Group (SWX:MOVE) reported unaudited first half 2026 revenue of €368 million, compared with €344 million a year earlier. This fresh trading statement is drawing attention to how the stock’s recent performance lines up with its underlying business trends.
See our latest analysis for Medacta Group.
Despite the latest revenue update, Medacta Group’s share price has weakened over 2026, with a year to date share price return of down 16.3% and a 1 year total shareholder return of down 9.2%, while the 3 year total shareholder return of 8.8% suggests longer term holders have seen modest gains.
If this kind of mixed momentum has you rethinking your watchlist, it could be a good moment to broaden your search and check out 106 top founder-led companies
Medacta Group’s revenue update sits next to a weaker share price and a sizeable gap to both analyst targets and intrinsic estimates. So where does fair value really look anchored when those reference points are this far apart?
Most Popular Narrative: 26% Undervalued
The most followed narrative for Medacta Group sees fair value at CHF179.08 compared with a last close of CHF132.60, which puts the recent revenue update into a wider context built on long term earnings and cash flow assumptions.
Expansion into new geographic regions with an increasing number of sales representatives and teams could drive revenue growth and optimize market penetration. Accelerated growth in the knee segment, particularly through the rollout of innovative products like the GMK SpheriKA, is expected to significantly impact revenue by capturing larger market share and pulling ahead of competitors.
Want to understand why this narrative still lands above the current CHF132.60 share price? The story leans heavily on compounded revenue gains, firmer margins and a richer future earnings multiple. Curious how those moving parts combine to support a CHF179.08 fair value and a double digit growth outlook on both the top and bottom line? The detailed narrative sets out the assumptions step by step so you can judge whether they stack up.
Result: Fair Value of CHF179.08 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you should keep in mind that expected orthopedic market softness and ongoing price pressure could weigh on Medacta Group’s margins and slow the narrative that analysts describe.
Find out about the key risks to this Medacta Group narrative.
Next Steps
Does the mix of softer recent returns and optimistic narratives around Medacta Group leave you unsure what to think yet keen to move quickly? Put the numbers in context and weigh the potential upside yourself by taking a closer look at the 4 key rewards.
Looking for more investment ideas beyond Medacta Group?
If Medacta Group has sharpened your focus on quality, you can use this moment to widen your search and uncover other opportunities that might suit your style.
Put these screeners to work now so you do not miss stocks that may fit your return goals and risk comfort.
- Identify potential mispricing early and review companies that currently screen as 255 high quality undervalued stocks before attention fully shifts their way.
- Prioritise resilience and assess businesses that appear in our 299 resilient stocks with low risk scores to help you stay focused when markets feel unsettled.
- Stay proactive and examine the screener containing 548 high quality undiscovered gems that combine solid fundamentals with lower visibility among investors.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com